Written by: Kirollos Hanna, PharmD, BCPS, BCOP, University of Minnesota Medical Center & Mayo Clinic
Ixazomib (Ninlaro®) is the only oral proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma after at least one prior therapy. This PQI highlights the management, safety, and efficacy of ixazomib.
Continue reading Ixazomib (Ninlaro®) in the Treatment of Multiple Myeloma
Written by: Jeremiah Moore, PharmD, University of Rochester Medical Center
This PQI will provide background on the novel medication selinexor for patients with multiple myeloma (MM) who have received at least one prior therapy, relapsed, refractory multiple myeloma (RR-MM), and relapsed, refractory diffuse large b-cell lymphoma (RR-DLBCL) and discuss effective practices to maximize the use of selinexor therapy.
Continue reading Selinexor (Xpovio®) Patient Management
Written by Julianne Orr, PharmD, Indiana University Health Simon Cancer Center
Olanzapine (Zyprexa) is an FDA approved atypical antipsychotic that blocks multiple neuronal receptors involved in nausea/vomiting pathways. This PQI will review the appropriate use of olanzapine for prevention and treatment of CINV.
Continue reading Olanzapine (Zyprexa) in Chemotherapy Induced Nausea and Vomiting